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Abstract
Background: Scleromyxoedema is a rare chronic skin disease of obscure origin, which may often
be associated with severe internal co-morbidity. Even though different casuistic treatment
modalities have been described, to date, curing still seems to be impossible.
Case presentation: We report a 44-year-old Caucasian female presenting with remarkable
circumscribed, erythematous to skin-coloured, indurated skin eruptions at the forehead, arms,
shoulders, legs and the gluteal region. Routine histology and Alcian blue labelling confirmed a
massive deposition of acid mucopolysaccharides. Immunohistochemical investigations revealed
proliferating fibroblasts and a discrete lymphocytic infiltration as well as increased dermal
expression of MIB-1+  and anti-mastcell-tryptase+  cells. Bone marrow biopsies confirmed a
monoclonal gammopathy of undetermined significance without morphological characteristics of
plasmocytoma; immunofixation unveiled the presence of IgG-kappa paraproteins.
Conclusions:  Taking all data into account, our patient exhibited a complex form of lichen
mxyoedematosus, which could most likely be linked a variant of scleromyxoedema. Experimental
treatment with methotrexate resulted in a stabilisation of clinical symptoms but no improvement
after five months of therapy. A subsequent therapeutic attempt by the use of medium-dose
ultraviolet A1 cold-light photomonotherapy led to a further stabilisation of clinical symptoms, but
could not induce a sustained amelioration of skin condition.
Background
Lichen myxoedematosus (LM) represents a rare chronic
skin disorder of unknown aetiology, which may often be
accompanied by severe internal co-morbidity such as hae-
matological involvement including paraproteinaemia,
neurologic syndromes, gastrointestinal complications or
cardiac abnormalities [1-4]. Clinically and histologically,
LM is characterised by papular eruptions caused by an
extensive dermal deposition of glycosaminoglycans [5].
Scleromyxoedema (SCL) is a variant of LM exhibiting ery-
thematous, sclerotic and stiffed lesions beside lichenoid
papules with only little tendency of spontaneous remis-
sion [6,7]. Even though various experimental treatment
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modalities have been described, to date, curing of SCL is
still not possible.
The oncoming case presentation focuses on a progressive
variant of SCL as referred to clinical, immunohistochemi-
cal and laboratory investigations, followed by low-dose
methotrexate (MTX) and subsequent medium-dose ultra-
violet A1 (UVA1) cold-light treatment.
Case presentation
We report a 44-year-old Caucasian woman who initially
presented in 2003 with a multitude of progressive
lichenoid 2–4 mm papules starting two years ago, partic-
ularly marked on the forehead right above both eyebrows,
on the dorsal aspects of the forearms, shoulders, legs as
well as on the gluteal region, accompanied by severe pru-
ritus (Fig. 1). Clinically, the papules were judged as dis-
crete, circumscribed, erythematous to skin-coloured, firm
skin eruptions associated with an induration and stiffen-
ing of the affected lesions. Furthermore, the patient com-
plained about a progressive thickening of the glabella.
Even though we cannot ensure continuous clinical deteri-
oration, at the time of the initiation of therapy, there was
no hint for a beginning stabilisation or even improvement
of symptoms. Otherwise, she felt healthy and well. The
general examination was without pathological findings.
Neither a topical nor a systemic therapy was yet applied.
Skin biopsies were taken from the left forearm/wrist, both
legs and the left shoulder. Routine histological examina-
tion including haematoxylin-eosin, PAS labelling and
Alcian blue staining revealed marked mucinous deposi-
tion within the upper and mid dermis beside an increased
appearance of fibroblasts, collagen bundles and a discrete
inflammatory infiltration.
Additionally, immunohistochemical investigations were
performed in order to enumerate CD4+ (T helper cells),
CD68+  (macrophages), anti-mastcell-tryptase+  (mast-
cells), decorin+ (collagen fibril stability protein), MIB-1+
Lichenoid papules beside thickened skin on the dorsal aspect of the left shoulder Figure 1
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(Ki-67+ proliferating cells), CD20+ (B lymphocytes), and
FGF-R+ (fibroblast growth factor receptor bearing cells)
cells taking consecutive sections (Table 1). A punch skin
biopsy measuring 3 mm in diameter was taken from
affected skin of the right forearm. 5 µm paraffin-embed-
ded sections were cut, mounted on slides and routinely
preserved. Prior to the single immunolabelling, different
pretreatments were performed for antigen retrieval (Table
1). The alkaline phosphatase anti-alkaline phosphatase
(APAAP) technique using the labelled streptavidin-biotin
(LSAB) method was used to enumerate immunopositive
cells at an individual dilution (Table 1) taking consecutive
sections. The alkaline phosphatase fast red detection kit
utilised a biotinylated secondary antibody that binds to
the primary antibody. This step was followed by the addi-
tion of an streptavidin enzyme conjugate binding to the
biotin present on the secondary antibody. Afterwards the
specific antibody-secondary-antibody-streptavidin-
enzyme-complex was detected using a precipitating
enzyme reaction product. Each step was incubated for a
precise time and temperature. The alkaline phosphatase
was used as enzyme; the chromogene fast red could be vis-
ualised. Cells were evaluated semiquantitatively (absent (-
), rare (o), moderate (+), frequent (++)) directly below the
dermoepidermal junction. Immunopositive cells were
evaluated 'blind' separately in two view fields in a row
(0.25 mm × 0.25 mm each) directly below the dermoepi-
dermal junction resulting in a length of 0.25 mm and 0.50
mm in depth. In order to avoid a sampling error, a
number of sections were randomly reevaluated by a sec-
ond observer. In case of a significant difference, the sec-
tions had to be recounted by both observers. In brief,
immunolabelling revealed occasional perivascular CD4+
and CD20+ lymphocytes located in the papillary dermis
and a high number of anti-mastcell-tryptase+ cells within
the subepithelial perivascular infiltrate revealing a contin-
uing decrease with increasing depth (Fig. 2). Simultane-
ously, an increased dermal expression of MIB-1+ cells (Fig.
3), morphologically predominantly fibroblasts, within
the upper and mid dermis and sporadic FGF-R+ cells in an
unspecific distribution could be detected. CD68 immuno-
histochemistry and intradermal decorin levels did not
alter remarkably as compared to healthy controls (data
not shown). Exact results of all immunohistochemical
stainings are detailed in Table 2.
Complete laboratory measurements unveiled the follow-
ing pathological results: leucocytes 10870 µL-1, lym-
phocytes 13.2%, IgG 2000 mg/dl. There was no increase
in B cell count. Immunoelectrophoresis disclosed albu-
min 51.4%, alpha-2 globuline 10.5%, gamma globuline
22.9%. Cranial x-ray, x-ray of the thorax, ultrasound of the
abdominal organs, electrocardiography and urinary inves-
tigations were unremarkable. Blood smear cytological
evaluation revealed beginning qualitative but still no
quantitative changes as defined by leukocytic aberrations
pointing towards a leftward shift. Serum immunofixation
demonstrated an IgG-kappa paraproteinaemia. No
elevation of the IgG-lambda paraprotein was assessed.
Bone marrow biopsies displaying reactive lymphoid infil-
tration including minimal extension of plasma cells with
monoclonal immunoglobuline production provided evi-
dence for monoclonal gammopathy of undetermined sig-
nificance (MGUS) without distinct morphological
characteristics of a plasmocytic plasmocytoma or
plasmoblasts.
Initially, 20 MHz ultrasound scanning producing cross
section images of the skin was established in order to
measure both structure and thickness of the skin at the
dorsal aspects of the left wrist and the right forearm. The
total thickness of the skin was measured from the
entrance echo to the border between the dermis and the
subcutaneous tissue. A cutaneous diameter of 2291 µm at
the left wrist (lesional skin) and of 1106 µm at the right
forearm (non-lesional skin) could be assessed.
In our unit, an experimental treatment modality using
oral MTX 12.5 mg once per week followed by a subse-
quent folic acid application on the following day for a 6-
Table 1: Overview about the performed immunohistochemistry (alkaline phosphatase anti-alkaline phosphatase (APAAP) technique 
using the labelled streptavidin-biotin (LSAB) method)
Antibody Source Pretreatment* Dilution Incubation time
CD4 Novocastra Loxo, Dossenheim, Germany H 1:60 30 min
CD68 Dako, Hamburg, Germany P 1:25 30 min
Tryptase Dako, Hamburg, Germany P 1:400 28 min
MIB-1 Dako, Hamburg, Germany H 1:10 32 min
FGF-R Oncogene Research, San Diego, USA N 1:10 30 min
Decorin Oncogene Research, San Diego, USA N 1:10 30 min
CD20 Novocastra Loxo, Dossenheim, Germany H 1:50 30 min
*N = none, P = protease digestion, H = heat (microwave-3-step-technique)BMC Dermatology 2004, 4:12 http://www.biomedcentral.com/1471-5945/4/12
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Immunhistochemistry unveiling sporadic lymphocytes beside a high number of anti-mastcell-tryptase+ cells within the subepi- thelial perivascular infiltrate Figure 2
Immunhistochemistry unveiling sporadic lymphocytes beside a high number of anti-mastcell-tryptase+ cells within the subepi-
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Mucinous deposition of the upper and mid-dermis accompanied by an elevated occurrence of MIB-1+ dermal fibroblasts Figure 3
Mucinous deposition of the upper and mid-dermis accompanied by an elevated occurrence of MIB-1+ dermal fibroblasts.BMC Dermatology 2004, 4:12 http://www.biomedcentral.com/1471-5945/4/12
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months-period was subsequently initiated. MTX was well
tolerated by our patient. After the first three months, the
continuous progress of skin lesions during the last two
years could be stopped and our patient experienced sub-
jectively an improvement and objectively a stable clinical
outcome without new lesions. Subjective impression of
amelioration could not be confirmed by means of ultra-
sound measurement. Within the following two months,
no further improvement could be evaluated, whereas no
further progression such as formation of new lesions or
increase of stiffness could be observed. Due to the unsat-
isfying clinical results and declining acceptance by our
patient, MTX treatment was stopped and a subsequent
therapeutic attempt with medium-dose UVA1 cold-light
phototherapy was initiated. Irradiation consisting of 50 J/
cm2 single-dose UVA1 (CL 300000 liquid, Photomed,
Hamburg, Germany) was performed four times a week for
three weeks followed by two times a week for further two
weeks resulting in a cumulative dose of 800 J/cm2 after
five weeks. Meanwhile, the skin status again remained sta-
ble, whereas no improvement could be observed. There-
fore, our patient broke up phototherapy. To date, skin
condition has slightly worsened without any current treat-
ment modality.
Conclusions
The population prevalence of SCL is known to be
extremely low. Skin lesions are characterised by an
increased deposition of acid mucopolysaccharides within
the papillary and upper reticular dermis [8]. Even today,
aetiology and pathogenesis remain hypothetic. Aberrant
dermal deposition of monoclonal paraproteins predomi-
nantly of the IgG subtype combined with elevated IgG
serum levels indirectly stimulating fibroblast activity are
frequently found in LM patients [9-11]. Nevertheless,
fibromucinous lesions of LM without the presence of par-
aprotein accumulations have also been described [12].
Beside typical skin eruptions, LM might also be associated
with severe internal and neurological abnormalities such
as cardiac irregularities, paralysis, hemiparesis or even
progress to coma [3,4,13]. Despite sporadic case reports
introducing new therapeutic strategies in LM and SCL,
common treatment modalities are still disappointing and
unsatisfactory. Topical treatment including hyaluronidase
and triamcinolone as well as systemic efforts by the use of
corticosteroids, cyclophosphamide, electron-beam ther-
apy, hydroxychloroquine, PUVA, extracorporeal photo-
pheresis, plasmapheresis or high-dose intravenous
immunoglobulin partly displayed only limited success in
individual patients [12,14-20].
In our patient, Alcian blue staining disclosed a remarkable
deposition of mucinous material within the upper dermal
layers combined with an increased appearance of prolifer-
ating MIB-1+ and occasional FGF-R+ fibroblasts in immu-
nohistochemistry. Ki-67 (MIB-1) and fibroblast growth
factors are involved in a variety of mitogen and prolifera-
tive activities [21]. Thus, the enhanced appearance of pos-
itive cells might represent an increased overall activation
probably resulting in an aberrant release of
mucopolysaccharides. Decorin contributes to the collagen
fibril stability and high levels of decorin seem to be closely
linked to dermal fibrotic stages as known from systemic
sclerosis [22]. Here, an increased intradermal decorin
expression could not be demonstrated. Simultaneously,
in our patient the mucinous deposition was accompanied
by a decreased presence of collagenous bundles. Interest-
ingly, immunohistochemistry also revealed a number of
CD4+ and CD20+ dermal inflammatory lymphocytes as
well as anti-human mast cell tryptase+ cells, which may
profoundly contribute to mucinosis formation [23].
Unfortunately, we were not able to provide a longitudinal
analysis of the different stainings due to missing consent
of the patient to perform additional experimental biopsies
within the course of therapy.
By considering clinical appearance, laboratory findings,
immunofixation, bone marrow biopsy and histological
evaluation, our patient presumably exhibited a complex
variant of SCL. Fibroblast activity was supposed to be
increased reflected by a corresponding high number of
MIB-1+ and FGF-R+ cells within the upper dermis beside a
massive mucinous deposition.
MTX therapy is approved in the treatment of malignant
lymphoma. Additionally, low-dose MTX therapy has been
established as a potent regimen in the treatment of T cell
Table 2: Semiquantitative data* of the immunohistochemical studies on a patient with scleromyxoedema
Antibody CD4 CD68 Tryptase MIB-1 FGF-R Decorin CD20
Upper dermis + o ++ + o - o
Mid-dermis - - + + - - -
L o w e r  d e r m i s o- oo- - -
*- = absent, o = rare, + = moderate, ++ = frequentBMC Dermatology 2004, 4:12 http://www.biomedcentral.com/1471-5945/4/12
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related skin diseases associated with a subsequent ele-
vated fibroblast activation status (e.g. progressive systemic
sclerosis) [24]. As in our patient paraproteinaemia of the
IgG-kappa class, morphological signs of MGUS, prolifer-
ating dermal fibroblasts and a discrete T cell weighted
lymphocytic dermal infiltration could be verified, we first
decided to start a therapeutic attempt by the use of 12.5
mg MTX weekly in order to suppress local cellular activity
following the promising reports about application of the
anti-metabolite melphalan and the alkylating agent cyclo-
phosphamide in previous studies [12,14]. Follow-up
examinations were performed monthly. Three months
after initiation of MTX therapy, an encouraging stable
clinical outcome as well as an decline of pruritus without
further progression of the disease was observed. However,
the 5-months-follow-up revealed no apparent improve-
ment of skin status leading to the joint decision of break-
ing up MTX treatment. UVA1 phototherapy has been
shown to be effective in a number of inflammatory and
fibrotic skin disorders by the induction of T cell apoptosis,
collagenase activity and antiproliferative pathways [25].
Therefore, we decided to initiate a second attempt by the
usage of a common medium-dose UVA1 irradiation pro-
tocol. Nevertheless, our patient broke up this regimen
even after a 5-weeks-period due to the absence of imme-
diate clinical improvement and an unfavourable time/
benefit ratio, while follow-up examinations during this
time revealed a stop of the progress anyway.
However, in order to interrupt the clinical progression or
even therapy-resistance as reflected by our case presenta-
tion and by considering the stable skin conditions follow-
ing UVA1 phototherapy, we are currently discussing a new
therapeutic attempt applying extracorporeal photochem-
otherapy, as proposed by Krasagakis et al. [16], in order to
stabilise or even improve the present slight aggravation
without any potent therapy.
List of abbreviations
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